Join Growin Stock Community!

Artivion, inc.AORT.US Overview

US StockHealthcare
(No presentation for AORT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AORT AI Insights

AORT Overall Performance

AORT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AORT Recent Performance

-1.74%

Artivion, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AORT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AORT Key Information

AORT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AORT Profile

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Price of AORT

AORT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AORT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.20
PE Ratio (TTM)
183.33
Forward PE
80.62
PS Ratio (TTM)
4.17
PB Ratio
4.11
Price-to-FCF
2157.21
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.40%
Net Margin
2.21%
Revenue Growth (YoY)
13.59%
Profit Growth (YoY)
14.25%
3-Year Revenue Growth
13.47%
3-Year Profit Growth
12.85%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.20
PE Ratio (TTM)
183.33
Forward PE
80.62
PS Ratio (TTM)
4.17
PB Ratio
4.11
Price-to-FCF
2157.21
Gross Margin
64.40%
Net Margin
2.21%
Revenue Growth (YoY)
13.59%
Profit Growth (YoY)
14.25%
3-Year Revenue Growth
13.47%
3-Year Profit Growth
12.85%

  • When is AORT's latest earnings report released?

    The most recent financial report for Artivion, inc. (AORT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AORT's short-term business performance and financial health. For the latest updates on AORT's earnings releases, visit this page regularly.

  • Where does AORT fall in the P/E River chart?

    According to historical valuation range analysis, Artivion, inc. (AORT)'s current price-to-earnings (P/E) ratio is 183.93, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of AORT?

    According to the latest financial report, Artivion, inc. (AORT) reported an Operating Profit of 7.18M with an Operating Margin of 6.19% this period, representing a growth of 169.01% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AORT's revenue growth?

    In the latest financial report, Artivion, inc. (AORT) announced revenue of 115.99M, with a Year-Over-Year growth rate of 19.2%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does AORT have?

    As of the end of the reporting period, Artivion, inc. (AORT) had total debt of 257.61M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AORT have?

    At the end of the period, Artivion, inc. (AORT) held Total Cash and Cash Equivalents of 64.91M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AORT go with three margins increasing?

    In the latest report, Artivion, inc. (AORT) achieved the “three margins increasing” benchmark, with a gross margin of 63.1%%, operating margin of 6.19%%, and net margin of 2.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AORT's profit trajectory and future growth potential.

  • Is AORT's EPS continuing to grow?

    According to the past four quarterly reports, Artivion, inc. (AORT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AORT?

    Artivion, inc. (AORT)'s Free Cash Flow (FCF) for the period is -7.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 191.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AORT?

    The latest valuation data shows Artivion, inc. (AORT) has a Price-To-Earnings (PE) ratio of 183.93 and a Price/Earnings-To-Growth (PEG) ratio of -3.52. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.